Involvement of gut microbiota in multiple sclerosis-review of a new pathophysiological hypothesis and potential treatment target.

IF 3.3 4区 医学 Q3 IMMUNOLOGY Immunologic Research Pub Date : 2024-08-01 Epub Date: 2024-03-06 DOI:10.1007/s12026-024-09471-y
Piotr Olejnik, Kasper Buczma, Agnieszka Cudnoch-Jędrzejewska, Kaja Kasarełło
{"title":"Involvement of gut microbiota in multiple sclerosis-review of a new pathophysiological hypothesis and potential treatment target.","authors":"Piotr Olejnik, Kasper Buczma, Agnieszka Cudnoch-Jędrzejewska, Kaja Kasarełło","doi":"10.1007/s12026-024-09471-y","DOIUrl":null,"url":null,"abstract":"<p><p>Multiple sclerosis (MS) is a chronic inflammatory disease that leads to demyelination and damage to the central nervous system. It is well known, the significance of the involvement and influence of the immune system in the development and course of MS. Nowadays, more and more studies are demonstrating that an important factor that affects the action of the immune system is the gut microbiota. Changes in the composition and interrelationships in the gut microbiota have a significant impact on the course of MS. Dysbiosis affects the disease course mainly by influencing the immune system directly but also by modifying the secreted metabolites and increasing mucosal permeability. The essential metabolites affecting the course of MS are short-chain fatty acids, which alter pro- and anti-inflammatory responses in the immune system but also increase the permeability of the intestinal wall and the blood-brain barrier. Dietary modification alone can have a significant impact on MS. Based on these interactions, new treatments for MS are being developed, including probiotics administration, supplementation of bacterial metabolites, fecal microbiota transplantation, and dietary changes. Further studies may serve to develop new drugs and therapeutic approaches for MS.</p>","PeriodicalId":13389,"journal":{"name":"Immunologic Research","volume":" ","pages":"554-565"},"PeriodicalIF":3.3000,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Immunologic Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s12026-024-09471-y","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/3/6 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Multiple sclerosis (MS) is a chronic inflammatory disease that leads to demyelination and damage to the central nervous system. It is well known, the significance of the involvement and influence of the immune system in the development and course of MS. Nowadays, more and more studies are demonstrating that an important factor that affects the action of the immune system is the gut microbiota. Changes in the composition and interrelationships in the gut microbiota have a significant impact on the course of MS. Dysbiosis affects the disease course mainly by influencing the immune system directly but also by modifying the secreted metabolites and increasing mucosal permeability. The essential metabolites affecting the course of MS are short-chain fatty acids, which alter pro- and anti-inflammatory responses in the immune system but also increase the permeability of the intestinal wall and the blood-brain barrier. Dietary modification alone can have a significant impact on MS. Based on these interactions, new treatments for MS are being developed, including probiotics administration, supplementation of bacterial metabolites, fecal microbiota transplantation, and dietary changes. Further studies may serve to develop new drugs and therapeutic approaches for MS.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
肠道微生物群在多发性硬化症中的参与--一个新的病理生理学假说和潜在治疗目标的回顾。
多发性硬化症(MS)是一种慢性炎症性疾病,会导致中枢神经系统脱髓鞘和损伤。众所周知,免疫系统的参与和影响对多发性硬化症的发生和发展具有重要意义。如今,越来越多的研究表明,影响免疫系统作用的一个重要因素是肠道微生物群。肠道微生物群的组成和相互关系的变化对多发性硬化症的病程有重大影响。菌群失调主要通过直接影响免疫系统来影响病程,但也通过改变分泌的代谢物和增加粘膜通透性来影响病程。影响多发性硬化症病程的重要代谢物是短链脂肪酸,它不仅会改变免疫系统的促炎和抗炎反应,还会增加肠壁和血脑屏障的通透性。仅饮食调整就能对多发性硬化症产生重大影响。基于这些相互作用,目前正在开发治疗多发性硬化症的新方法,包括服用益生菌、补充细菌代谢产物、粪便微生物群移植和改变饮食。进一步的研究可能有助于开发治疗多发性硬化症的新药物和治疗方法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Immunologic Research
Immunologic Research 医学-免疫学
CiteScore
6.90
自引率
0.00%
发文量
83
审稿时长
6-12 weeks
期刊介绍: IMMUNOLOGIC RESEARCH represents a unique medium for the presentation, interpretation, and clarification of complex scientific data. Information is presented in the form of interpretive synthesis reviews, original research articles, symposia, editorials, and theoretical essays. The scope of coverage extends to cellular immunology, immunogenetics, molecular and structural immunology, immunoregulation and autoimmunity, immunopathology, tumor immunology, host defense and microbial immunity, including viral immunology, immunohematology, mucosal immunity, complement, transplantation immunology, clinical immunology, neuroimmunology, immunoendocrinology, immunotoxicology, translational immunology, and history of immunology.
期刊最新文献
Investigating the link between Helicobacter pylori infection and psoriatic disease: an immunological study. RAD001-mediated mTOR targeting in human monocyte-derived dendritic cells shifts them toward an immunogenic phenotype. Regulation of PDL-1 expression in thyroid carcinoma cells by tumor cell derived cytokines activating STAT3. SARS-CoV-2 pathophysiology and post-vaccination severity: a systematic review. A patient with CVID-enteropathy successfully treated with ustekinumab.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1